Martingale Asset Management L P Cuts Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Martingale Asset Management L P lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 24.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,177 shares of the specialty pharmaceutical company's stock after selling 8,563 shares during the period. Martingale Asset Management L P owned 0.12% of ANI Pharmaceuticals worth $1,447,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ANIP. Exchange Traded Concepts LLC grew its holdings in shares of ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after buying an additional 310 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares during the last quarter. Natixis Advisors LLC increased its holdings in shares of ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after purchasing an additional 417 shares in the last quarter. US Bancorp DE raised its stake in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after purchasing an additional 531 shares during the last quarter. Finally, KBC Group NV lifted its holdings in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

ANIP has been the subject of several research analyst reports. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Guggenheim restated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Friday. StockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, April 8th. Finally, Jefferies Financial Group began coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $79.75.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded up $0.83 during mid-day trading on Tuesday, hitting $69.55. 191,896 shares of the company traded hands, compared to its average volume of 269,229. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock's fifty day moving average price is $62.71 and its 200-day moving average price is $59.22. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -126.45 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.00.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $197,792 in the last ninety days. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.